Roivant Announces Results From Its Phase 2 PHocus Clinical Trial Evaluating Mosliciguat For Treatment Of Pulmonary Hypertension Associated With Interstitial Lung Disease; PHocus Met Its Primary Endpoint, Demonstrating Clinically Meaningful And Statistically Significant Placebo-Adjusted Reduction In Pulmonary Vascular Resistance
"PH-ILD remains one of the most challenging forms of pulmonary hypertension to treat, given the heterogeneity of the disease and the fact that existing therapies are approved in limited geographies and poorly
Roivant's medicine test for a serious lung disease showed it worked better than a fake pill, which is a good sign the medicine might help patients. When a company's medicine passes an important test like this, it's worth watching to see if it gets approved by doctors and if patients actually use it.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.